Background. Brain injury in newborn animals from prolonged anaesthetic exposure has raised concerns for millions of children undergoing anaesthesia every yr. Alternative anaesthetic techniques or mitigating strategies are urgently needed to ameliorate potentially harmful effects. We tested dexmedetomidine, both as a single agent alternative technique and as a mitigating adjuvant for sevoflurane anaesthesia. Methods. Neonatal rats were randomized to three injections of dexmedetomidine (5, 25, 50, or 100 mg kg À1 every 2 h), or 6 h
Before human application, new medical products, devices, and drugs are typically rigorously tested in animal models to identify potential toxicity and safety concerns. As preclinical and even clinical testing specifically for paediatrics is often lacking, much of paediatric medicine relies on off-label use of conventional therapies that have been previously approved for adult applications. Thus, the growing number of animal studies over the past two decades, demonstrating brain structural and cognitive abnormalities in a wide variety of species after prolonged anaesthetic exposure early in life, have raised substantial concerns regarding the safe use of these drugs during paediatric anaesthesia, particularly in infants and young children undergoing life-saving surgeries (recently reviewed in 1 ). However, the immediate clinical translatability of these laboratory findings remains undetermined. 2 3 All commonly used general anaesthetics, including sevoflurane, the most frequently used anaesthetic in paediatric practice, have been found to cause widespread apoptotic neuronal death and to alter dendritic architecture, and deficits in long-term cognitive and behavioural function in animals, including small rodents and nonhuman primates, after exposures of up to six h early in life. [4] [5] [6] [7] [8] [9] [10] Structural brain injury in these animal studies was found after prolonged exposures to sevoflurane in doses of 2.5% to 4%. Clinical investigations, on the other hand, have been equivocal. The only clinical trial specifically focusing on sevoflurane has not demonstrated any detrimental effects on interim cognitive outcomes two yr after a one-h exposure to sevoflurane for inguinal hernia repair in infancy. 11 While some epidemiological studies examining early life exposures to a variety of anaesthetic drugs, including sevoflurane, have associated anaesthetic exposures and subsequent abnormalities in learning, cognition, or brain structure, 12 13 others have not found demonstrable cognitive impairment.
14 Despite a lack of strong confirmatory findings in human studies, additional research into better understanding developmental anaesthetic neurotoxicity are urgently needed, because of several concerns. Firstly, the developing brain is exquisitely sensitive to deleterious effects during prolonged or repeated exposures, yet anaesthetics and sedatives are used in millions of young children for surgeries that cannot be postponed until a potentially less vulnerable older age. Secondly, no general anaesthetic has been identified in animal studies to be unequivocally non-injurious, leaving paediatric clinicians no alternative agents. Lastly, no biological tenet exists that would exempt humans from the structural and cognitive abnormalities observed after prolonged anaesthetic exposures in all animal species that have been tested, including non-human primates. Accordingly, in 2008 the US Food and Drug Administration (FDA) and the International Anesthesia Research Society (IARS) formed SmartTots, a public-private partnership to coordinate and fund research into this growing paediatric health concern. Moreover, in December 2016 the FDA published a warning that repeated or lengthy exposures to general anaesthetics or sedative drugs in children < three yr of age might adversely affect their brain development, underscoring the need for additional studies. Given the strong evidence and serious potential ramifications of paediatric exposures to anaesthetics or sedatives for patients, care providers, and society, it seems prudent to not only attempt to identify safer, alternative anaesthetic techniques in animals, but also to develop mitigating strategies or adjuvants to ameliorate potentially harmful anaesthetic effects. If experiments in model species found strong evidence for safe alternative strategies, human trials could start promptly. Among several potential pharmacological targets, dexmedetomidine is a promising candidate, because it provides sedation via a 2 -receptor agonism and therefore avoids NMDA-receptor antagonism or GABA A -receptor potentiation characteristic of drugs implicated in deleterious anaesthetic effects. Moreover, dexmedetomidine has been found to protect the brain during hypoxic-ischaemic insults and to alleviate some of the toxic effects observed during isoflurane exposure. [15] [16] [17] [18] [19] Several important uncertainties remain regarding dexmedetomidine's widespread use, including its limited effectiveness as a sedative when utilized in isolation. Furthermore, its interactions with sevoflurane, the most frequently used inhaled anaesthetic in paediatric anaesthesia, have not been fully elucidated. We therefore tested the hypothesis that dexmedetomidine as the sole sedative agent during a six-h exposure in neonatal rodents, even in high doses, would not affect structural integrity in several brain regions previously identified to be vulnerable to anaesthesia-induced abnormalities, while providing adequate anaesthetic depth and stable vital signs. We further expected dexmedetomidine co-administration to protect from the deleterious effects of 2.5% sevoflurane. This dose was selected as a clinically applicable dose, that has previously been shown to induce injury in order to test dexmedetomidine's protective effects as a mitigating adjuvant, independent of its sevoflurane-sparing properties.
In order to address recently raised concerns regarding proper reporting of animal studies, difficulties in replicating results, and their questionable translational value for clinical practice, this study followed the Animal Research Reporting In Vivo Experiments (ARRIVE) guidelines. 20 We also took the unique approach to concurrently plan and conduct two parallel studies with the same goals in two separate animal laboratories, utilizing the respective methodologies available to each research
Editor's key points
• Sevoflurane and other volatile anaesthetics cause widespread neuronal death in young animals of multiple species.
• Treatment of neonatal rats with sevoflurane alone increased neuroapoptosis, while dexmedetomidine alone produced restricted neuroapoptosis at high doses.
• However, dexmedetomidine dose-dependently enhanced sevoflurane-induced neuroapoptosis, and increased mortality.
• Dexmedetomidine enhanced anaesthetic neurotoxicity, perhaps as a result of physiological derangement or enhanced anaesthetic depth.
group. We envision the results of the current study to inform future cognitive rodent studies, non-human primate studies, and subsequent clinical trials to develop safer clinical paediatric anaesthesia practice involving dexmedetomidine-based techniques.
Methods

Animals
Wistar rat breeding pairs were obtained from Charles River Laboratories International, Inc. (Worcester, MA, USA), housed in a 14 h light-10 h dark cycle (lights on at 7 am) at 22 C, with free access to food and water. Offspring remained with their parents until day of life seven (P7, with P0 representing date of birth) when they were randomized using a computer-generated chart to one of ten treatment groups. Randomization was blocked by mating pairs. Litter sizes ranged from 10-14 animals, so at least one animal from every litter was assigned to each treatment group. Body weights were between 9.5 and 17.5 grams. Animals of both sexes were used, but the number of treatment groups precluded blocking by sex. A total of 102 animals were used, with group sizes of n¼10-11. Experiments followed the National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committee of the Cincinnati's Children's Research Foundation. The protocol met the criteria of the ARRIVE guidelines. 20 
Exposure protocol
On P7, rats were randomly allocated to one of ten, six-h exposure protocols: sevoflurane 2.5% (Sevo 2. , Precedex, Pfizer, New York, NY, USA) with preservative-free normal saline to a final concentration of 1 -20 mg ml À1 , to limit the maximum volume of injection to 0.1 ml. All animals were kept in a 30% oxygen environment in an acrylic chamber within a heated incubator set at 34-36 C to maintain rectal temperature 36. selected to examine neuroapoptosis in previously identified regions specifically susceptible to anaesthetic exposure, including prefrontal cortex, retrosplenial cortex, somatosensory cortex, hippocampal CA1, CA2-3, laterodorsal and ventral thalamic nuclei, and subiculum (Fig. 1A) . Slides containing the selected sections were stained for activated cleaved caspase 3 (AC3), neuronal nuclei (NeuN), and 4',6-diamidino-2-phenylindole (DAPI). AC3 is the executioner caspase and a marker of commitment to apoptotic cell death. NeuN represents a neuron-specific marker of post-mitotic development. DAPI is a fluorescent stain that binds strongly to A-T rich regions in DNA, labelling cellular nuclei. All sections were treated with PBS with 5% Tween-20, 5% triton, 1% SDS, and 0.1% tris(2-carboxyethyl)phosphine for 16-18 h at room temperature, followed by incubation for 20 min at 100 C in a 1:10 dilution of sodium citrate buffer at pH 6.0 (CB910 
Quantification of apoptosis
Three-channel confocal image stacks of triple-immunostained sections were collected through the Z-depth of the tissue from the regions of interest, using a Nikon Eclipse Ti inverted confocal microscope equipped with an A1R controller (Nikon Instruments Inc., Melville, NY, USA) with a 20 x, 1.2 NA objective. Regions were outlined as defined in Fig. 1 and images were collected with a x 1 optical zoom, in 0.5 mm steps, format 1024*1024. DAPI was excited using the 405 nm laser line, and emission wavelengths were between 358 to 461 nm. Quantification of degenerating neurones that were colabelled with the apoptotic executioner caspase 3, the neuronal marker NeuN, and the nuclear marker DAPI performed by unbiased stereology using the optical disector method after confocal microscopy imaging of z-stacks throughout entire tissue sections. Cells were excluded from counts if they transected the three exclusion planes (top, back, and right side, represented by "x" in schematic) and were included if located within the counting frame or transecting the other three sides of the frame (labelled with check marks in schematic). Density counts were calculated using tissue volume determined in Neurolucida using the counting dimensions and width of the tissue, and were averaged for each experimental group by brain region.
AC3 immunostaining was excited using 488 nm laser line, and emission wavelengths were captured between 495 and 550 nm. NeuN immunostaining was excited using the 633 nm laser line with collecting emission wavelengths between 650 and 710 nm.
Resulting image stacks were transferred to image analysis software (Neurolucida v10.31, MBF Bioscience, Williston, VT, USA) and assessed by three investigators unaware of group assignment. The number of apoptotic, AC3-positive neurons with DAPI and/or NeuN co-staining were quantified using the optical disector method (Fig. 1B) . 7 22 23 Densities of apoptotic cells were quantified as cells per mm 3 of examined tissue for each animal and group-averaged for each examined brain regions. Efforts were made to reduce bias, such as de-identifying samples to keep the observer assessing the immunohistochemical samples unaware of group assignments. Furthermore, the respective sections were scanned for all animals with the channel that displayed caspase expression hidden. Several regions were counted by two investigators to verify external validity of the quantification process.
Statistical analysis
Sample sizes for group assignment were made a priori; based on previous experiments, n¼7-8 animals per group would be required to reach a significance level of 5% with 80% power on a two-sided test. Data are presented as mean (SEM) or percentage, as applicable. Data were tested for normality using the WilkShapiro test. While all figures show data as mean (SEM) to facilitate visual comparisons, appropriate statistical analyses were used. Rates of neuronal apoptosis were compared between groups using Kruskal-Wallis rank test with Dunn's test for multiple comparisons. Group comparisons of vital signs, including heart rate and peripheral oxygen saturation level, utilized repeated measures one-way ANOVA with Bonferroni's correction. Ordinal data, including LORR and pain response, were analysed using the Friedman test with Benjamini-Hochberg's correction for multiple comparisons. Categorical data, such as mortality, were compared using Fisher's exact test. All analyses were performed using Stata v10.1 (StataCorp, College Station, TX, USA). Statistical significance was defined as P<0.05.
Results
All animals injected with normal saline or dexmedetomidine alone survived the six h exposures, as did animals anaesthetised with 2.5% sevoflurane by itself or in combination with repeated injections of 1 mg kg À1 of dexmedetomidine (Table 1) .
However, dexmedetomdine in doses of 5, 10, or 20 mg kg À1 with 2.5% sevoflurane led to significant mortality, without differences between these three groups (P¼0.5). Qualitatively, mortality seemed associated with the repeated injections of dexmedetomidine at doses exceeding 1 mg kg À1 at 120 and 240 min of sevoflurane exposure (Fig. 2) . Measuring vital signs throughout the six-h exposures revealed that heart rate was 250-350 beats min À1 and did not change throughout the exposure period regardless of group assignment (Fig. 3) . Heart rate was significantly lower in animals injected with the two highest dexmedetomidine doses (50 or 100 mg kg À1 , injected every two h for three times) compared with control animals (injected with normal saline) or animals anaesthetised with sevoflurane (Fig. 3) . Addition of dexmedetomidine at doses exceeding 1 mg kg À1 every two h to sevoflurane also decreased heart rate compared with those administered sevoflurane by itself. Dexmedetomidine treatment, in any dose, or sevoflurane by itself, did not decrease peripheral oxygen concentration compared with control animals. However, cotreatment of dexmedetomidine in doses of 5, 10, or 20 mg kg À1 with 2.5% sevoflurane significantly diminished oxygen saturation (Fig. 3) . Quantification of the level of sedation, measured by repeated evaluations of the righting reflex, demonstrated substantial differences in level of consciousness between groups (Fig. 4) . Dexmedetomidine 5 mg kg À1 every two h did not significantly diminish consciousness compared with saline-injected control animals, whereas doses of 25 mg kg À1 or greater led to significant sedation. All animals anaesthetised with sevoflurane demonstrated a greater level of sedation compared with any dexmedetomidine doses, even the highest. Similarly, while all dexmedetomidine doses decreased the response to painful stimulation compared with control animals, sevoflurane abolished pain responses to a significantly higher degree compared with even the highest dexmedetomidine dose. Histological analysis was performed only in animals surviving the six-h anaesthetic exposure. Similar to previous studies, a six-h exposure to 2.5% sevoflurane resulted in significantly increased neuronal apoptotic cell death in all evaluated brain region, as measured by activated caspase 3 expression compared with control ( Figs 5-7) . In contrast, a six-h exposure to dexmedetomidine as a single agent, even in the highest dose, did not significantly raise apoptotic neuronal cell death above the level observed in saline-injected animals for most brain regions, except for the ventral posterior nucleus of the thalamus and the CA2/3 region of the hippocampus, where increased neuroapoptosis was observed (Fig. 6) . While a six-h exposure to 2.5% sevoflurane led to a greater number of apoptotic, activated caspase 3-expressing neurons than a six-h exposure to the highest dexmedetomidine dose (three injections of 100 mg kg À1 )
in prefrontal cortex, somatosensory cortex, and CA2/3, the level of apoptosis was indistinguishable between these two treatments in four other regions, including retrosplenial cortex, Table 1 Mortality of seven day-old rat pups during six h exposure to dexmedetomidine or sevoflurane by itself or in combination. Seven day-old Wistar rats were assigned to receive three injections every two h of normal saline (Dex 0), or ascending doses of 5 to 100 mg/kg of dexmedetomidine (Dex 5 to Dex 100), or were anaesthetized with 2.5% sevoflurane without (Sevo 2.5) or with dexmedetomidine supplementation in doses from 1 to 20 mg/kg every 2 h (Sevo 2. 10  10  10  11  10  10  10  11  10  10  Mortality  0%  0%  0%  0%  0%  0%  0%  18%  30%  40% subiculum, hippocampal CA1, ventral posterior nucleus, and lateral dorsal nucleus of the thalamus (Fig. 7) . In general, increasing the dose of dexmedetomidine by itself seemed to only slightly raise the number of caspase-expressing neurons, while adding increasing doses of dexmedetomidine to sevoflurane significantly increased the level of apoptosis in all examined brain regions, except for CA2/3, where the increase did not reach statistical significance.
Discussion
Deleterious effects of all routinely used anaesthetic agents on brain structure and cognitive function observed in developing animals have raised tremendous concerns for paediatric anaesthesia practice. Abnormalities were most noticeable after prolonged or repeated exposures in very young animals. 1 Given the abundant confounders affecting young children requiring surgery with anaesthesia, the ethical limitations of clinical studies, and the substantial differences between all model species and clinical practice, 24 it remains unresolved whether results from animal studies can be directly applied to paediatric anaesthesia practice. 25 26 However, the serious individual and societal ramifications of any potential detrimental effects of anaesthetic exposure on human brain structure and subsequent cognitive performance, justify every effort to develop safer anaesthetics and devise mitigating strategies, even when it remains unclear whether similar structural effects occur in children undergoing prolonged or repeated anaesthetic exposures. As laboratory findings can vary substantially among studies and between research laboratories, it is necessary to replicate results in different labs before recommending interventional strategies for testing in non-human primates or human clinical trials. Accordingly, the present study was designed to compare the structural effects of dexmedetomidine and sevoflurane in several brain regions with the unique approach of performing the study simultaneously in two separate laboratories, utilizing each group's respective expertise in studying the effects of anaesthetics on the developing brain. This approach was taken because of previous animal studies from different laboratories demonstrating conflicting results, such as comparing the relative neurotoxic potencies between desflurane, sevoflurane, and isoflurane. 7 8 27 We expected the similar design and parallel execution of our study in the respective laboratories to lead to more homogeneous results. The a 2 -agonist dexmedetomidine was selected for its lack of interaction with GABA A -or NMDA-glutamate receptors, both of which have been implicated in the abnormalities observed during prolonged anaesthetic exposures. Moreover, dexmedetomidine has previously been found to confer protective effects during brain ischaemia, 15 to reduce ketamine-induced neuroapoptosis and learning impairment, 19 and to ameliorate deleterious structural and cognitive effects of isoflurane exposure. 16 17 In the case of ketamine, single injections of 75 mg kg À1 of ketamine and 25 mg kg À1 of dexmedetomidine on three consecutive days between P7 and P9 were studied in neonatal rats. 19 During a six-h exposure to 0.75% isoflurane, approximately 0.3 MAC in newborn rats, dexmedetomidine doses of 25, 50, and 75 mg kg
À1
injected every two h protected from cortical apoptosis in seven day-old pups. 17 Dexmedetomidine (25 mg kg À1 every two h) did not significantly increase the number of apoptotic, caspase 3-expressing cells in neocortex. 17 In foetal cynomolgus monkeys, a prolonged dexmedetomidine exposure of 3-30 mg kg À1 h À1 for 12 h did not induce significant apoptosis in layers I-III of the frontal cortex. 28 In contrast, 30-45 mg kg À1 of dexmedetomidine injected six times in 90-min intervals produced significant cellular degeneration and apoptosis in sensory thalamus and primary sensory cortices, but nonsignificant changes in limbic brain regions in neonatal rats. 29 However, dexmedetomidine has not yet been compared with the most frequently used anaesthetic in paediatric anaesthesia, sevoflurane, which has been shown to induce widespread neurodegeneration and caspase activity, 7 8 30 to cause ultrastructural changes, 6 31 32 and to produce long-term cognitive and behavioural abnormalities in small rodents and non-human primates after exposure early in life. 4 9 10 Accordingly, the present study examined the effects of repeated dexmedetomidine injections of 5, 25, 50, or 100 mg kg
every two h as a single agent and the combination of 1, 5, 10, or 20 mg kg À1 dexmedetomidine every two h with 2.5% sevoflurane compared with a 2.5% sevoflurane-only group and unanaesthetised controls.
The potency of inhalation anaesthetics in rodents is comparable with human minimum alveolar concentrations (MAC). The concentration of sevoflurane used in the present study was 0.6-0.7 MAC. 33 Conversely, small animals require substantially higher weight-based doses of injectable anaesthetics and sedatives, and it is difficult to translate these doses for use in clinical practice. 34 Moreover, the small size of the animals renders continuous parenteral administration of a mild sedative challenging. Accordingly, we elected to study repeated doses of dexmedetomidine from 5 to 100 mg kg
. As a result of concerns for reductions in heart rate observed with dexmedetomidine, especially at higher doses, and the possibility for anaesthesiainduced decreases in oxygen saturation, especially with the combination of sevoflurane and dexmedetomidine, heart rate and peripheral oxygen saturation were also measured intermittently throughout exposure. While the duration of six h was outside of routine paediatric anaesthetic exposures, it represents the most frequently studied exposure time for laboratory 
Comparison of neuronal apoptosis
Dexmedetomidine, even in escalating doses up to 50 mg kg À1 h
À1
for six h (injected in doses of up to 100 mg kg À1 every two h for three times) affected neuronal apoptosis to a much lesser degree than sevoflurane, as measured by cellular expression of the executioner caspase 3 in a variety of brain regions. This is consistent with previous studies observing less caspase 3 expression after three injections of 25 mg kg À1 dexmedetomidine compared with 0.75% of isoflurane. 17 It extends these previous observations to higher cumulative dexmedetomidine doses of up to 300 mg kg
injected over a period of six h. Even at this highest dose of dexmedetomidine, neuronal injury was indistinguishable from saline-injected control animals in all but two brain regions, the ventral posterior nucleus of the thalamus and hippocampal CA2/ 3. A specific vulnerability of the ventroposteriomedial thalamus has also recently been observed after exposure to six injections of 45 mg kg À1 (a cumulative dose of 270 mg kg
) dexmedetomidine, 29 while susceptibility of the hippocampus has previously not been reported. The present findings contrast somewhat with recent observations of dexmedetomidine-induced neuroapoptosis in somatosensory cortex after cumulative doses of 50 to 250 mg kg À1 in seven day-old Sprague-Dawley rats. two h during a clinically applicable dose of sevoflurane, as no reduction in caspase-positive neurones was observed in any of the examined brain regions. It is not clear why our results differ from previous studies demonstrating protective effects during a six-h exposure to 0.3 MAC of isoflurane. 17 Possible explanations are that a dose of 0.6 MAC sevoflurane (2.5% in seven day-old rats) exceeded the protective abilities of dexmedetomidine, or that methodological differences during exposure or histological analysis led to the contrasting results. Additionally, neuronal apoptosis increased in our study when dexmedetomidine supplementation exceeded 10 mg kg À1 every two h, most likely as a result of increased depth of anaesthesia with concomitant ventilatory and haemodynamic compromise, as evidenced by increased mortality, indicating the need for meticulous monitoring of vital signs. The relative contributions of anaesthetics or physiological derangements are difficult to separate in small rodents, and it was impossible to establish the exact dose at which physiological derangements secondary to inadequately deep levels of anaesthesia in the combined groups affected neuropathology. Mortality increased in animals treated with supplemental dexmedetomidine doses of 5 mg kg À1 or higher, whereas neuronal apoptosis did not significantly increase in survivors until doses of 20 mg kg À1 were administered.
Vital signs
Dexmedetomidine can lead to significant decreases in heart rate; however, our data suggest that this effect is not observed in newborn rats until doses of !50 mg kg À1 are administered.
Even using the highest dose, dexmedetomidine only reduced heart rate from the baseline of $300 beats min À1 in control animals to $260 beats min
À1
, similar to recent findings, 35 suggesting that cardiac output was likely maintained. We did attempt to measure bp non-invasively during exposure, but were unable to do so consistently (data not shown) because of the small body size and short tail length at this age. Similarly, addition of dexmedetomidine doses of ! 5 mg kg À1 to 2.5% sevoflurane led to a significant reduction in heart rate compared with sevoflurane alone. Addition of 5, 10, or 20 mg kg À1 of dexmedetomidine to 2.5% sevoflurane also resulted in reduced oxygen saturation, suggesting that these combined doses cause an unsafe depth of anaesthesia, hypoventilation, and potentially hypoxic brain injury, thereby confounding the effects of the anaesthetics. This concern is supported by the significant mortality observed during the combination exposure with !5 mg kg À1 dexmedetomidine. Pilot experiments established that addition of 25 or 50 mg kg À1 of dexmedetomidine to 2.5% sevoflurane was lethal.
Conversely, dexmedetomidine alone, even in the highest doses, did not significantly decrease oxygen saturation or increase mortality. However, the unexpectedly low peripheral oxygen saturations of 85-90% in control animals question whether current technology is capable of adequately monitoring oxygenation in newborn small rodents or whether dehydration of neonatal animals during prolonged separation from the dams might have contributed. The physiological derangements observed with !5 mg kg À1 dexmedetomidine plus anaesthetising concentrations of sevoflurane suggest that future studies into the protective effects of dexmedetomidine need to decrease doses of inhalation anaesthetics to account for dexmedetomidine's MAC sparing effect. This will render quantification of dexmedetomidine's protective effect difficult, as it will then be utilised in an anaesthetic-sparing fashion. However, this approach will nonetheless be informative from a translational standpoint, as it could lead to substantial dose reductions of a potentially injurious inhaled anaesthetic and could also be relatively easily adopted for clinical practice.
Level of sedation and pain response
Significant questions regarding dexmedetomidine's sedative potency currently prevent its use as a solitary drug during painful and invasive procedures in children. Our data demonstrate that, while the lowest dose of dexmedetomidine (5 mg kg À1 every two h) reduced the response to painful stimulation, it did not consistently cause a loss in righting reflex. As awake rodents, even in infancy, possess an innate urge to right themselves when inverted, the presence of this labyrinthine reflex is frequently used as a measure of consciousness. Dexmedetomidine diminished this reflex only when repeated doses exceeded 5 mg kg
À1
, and even the highest doses of 100 mg kg À1 did not result in the same loss of responsiveness as 2.5% sevoflurane.While all doses of dexmedetomidine reduced the response to painful stimulation, even repeated injections of the highest dose did not block pain responses as 2.5% sevoflurane did, suggesting that dexmedetomidine did not produce the same level of anaesthesia. These findings are consistent with clinical experience that additional sedatives and/or analgesics must be administered concurrently with dexmedetomidine for invasive procedures. These results also suggest that differing levels of toxicity between sevoflurane and dexmedetomidine could be related to their differing anaesthetic potency, as similar degrees of anaesthesia-induced cell death occur after exposures to equi-anaesthetic doses of desflurane, isoflurane, or sevoflurane despite their differing inhaled concentrations.
7
Cooperative study design
We performed parallel experiments in two separate laboratories using different species and each team's respective methodologies in order to compare findings from two different research groups. 36 The research plan was devised jointly between the two laboratories to minimize methodological differences. Both study sites observed increases in neuroapoptosis after prolonged exposure to a clinically relevant dose of sevoflurane in all brain regions examined. Similarly, both studies found a six-h exposure to dexmedetomidine, even in escalating doses, to not significantly increase neuronal apoptosis for most examined brain regions. Both studies observed deleterious effects of adding dexmedetomidine at ! 5 mg kg À1 to sevoflurane on oxygenation and survival. However, the findings of the two studies substantially differed in the potential protective effects of adding a lower dose of dexmedetomidine to sevoflurane. While our laboratory did not observe any reduction in neuronal cell death in any of the examined brain regions with 1 or 5 mg kg À1 dexmedetomidine every two h during a six-h exposure to 2.5% sevoflurane, the parallel study demonstrated significant reduction in neuroapoptosis using this same drug regimen. 36 It is unclear why the two studies differed on this particular result. Possibilities include methodological differences, such as differences in animals, staining protocols, painful stimulation, or the approach for caspase 3 quantification. This discrepancy is especially difficult to explain, as all other findings involving relative cellular density counts were comparable. This important discrepancy suggests that future studies need to put particular emphasis on establishing reproducible quantification methods for cellular density counts and consider a similar parallel setup in order to maximize external validity. While not congruent, our findings warrant further studies into the potential protective effects of low-dose dexmedetomidine co-administered with clinically relevant or reduced concentrations of inhaled anaesthetics.
Limitations
The current study in small rodents has several limitations, including the limited ability to monitor vital signs during exposure. Apoptotic cell death is the primary mode of neuronal death in the immature brain, regardless of whether triggered by hypoxia-ischaemia or anaesthetic exposure. Without the ability to exclude physiological derangements, it is difficult to distinguish between these two aetiologies. Mortality occurred when supplemental dexmedetomidine doses of 5 mg kg À1 or higher were used in conjunction with sevoflurane, and seemed to occur after repeat injections of dexmedetomidine, suggesting that inadequately deep levels of anaesthesia could have affected survival in these groups. Neuronal apoptosis increased significantly in the majority of brain regions when doses of 20 mg kg À1 of dexmedetomidine were used, which indicates that brain injury secondary to physiological abnormalities increased anaesthesia-induced neurodegeneration at this highest dose. It is unclear whether this also affected density of apoptotic neurons in the sevoflurane group injected with 5 mg kg À1 dexmedetomidine, which was statistically indistinguishable from sevoflurane as a single agent. It is therefore difficult to distinguish the relative contributions of anaesthetics and physiological derangements on neurodegeneration and their interactions. However, neuronal injury patterns in unmonitored small rodents and in monitored, intubated, and ventilated nonhuman primates have previously been found to be qualitatively similar, 37 suggesting that anaesthesia-induced neuroapoptosis can be studied in small rodents using clinically relevant doses of inhaled anaesthetics. Importantly, even performing studies in non-human primates with adequate ventilatory and haemodynamic control might not entirely resolve whether dexmedetomidine should be used as an ameliorating treatment in humans, as it is not clear whether neuronal apoptotic cell death represents an early manifestation of behavioural or cognitive abnormalities observed months and yr after anaesthetic exposure. Accordingly, it will be critical for future studies, both rodent and non-human primate, to include cognitive outcomes. Our study included intermittent painful stimulation to measure depth of anaesthesia, which most small rodent studies do not. While it remains uncertain whether concurrent noxious stimulation exacerbates, 38 39 ameliorates, 40 41 or does not affect neuronal injury secondary to anaesthetic exposure, 42 the intermittent paw clamping and concomitant soft tissue irritation could have altered the neuronal injury observed and the effects of dexmedetomidine coadministration in comparison to studies not applying painful stimuli throughout exposure. Absolute neuronal cell counts of the entire brain are extremely difficult, so our quantification relied on a sampling strategy which assumed tissue samples were representative of the brain region of interest as a whole. We used a well-validated stereological counting method that unequivocally identified neurones as the apoptotic target. Even so, regional neuronal vulnerability changes with age and injury pattern and protective effects at other ages might differ from the current results obtained in seven day-old rats. 43 Timing and pace of brain maturation differ by brain region and by species, and substantial brain developmental events occur in utero in humans and postnatally in small rodents. The stages of human brain development equivalent to the rat pups used remain under intense investigation, but probably relate to the premature brain during the third trimester of pregnancy. 44 Accordingly, the observed injury might not have direct translational relevance to children undergoing anaesthesia at a later age. While doses for inhaled anaesthetics are comparable between animal species and humans, much higher doses for injectable anaesthetics and sedatives, such as dexmedetomidine, are required to obtain a therapeutic effect in small animals. It is therefore unclear whether toxicological findings involving injectable anaesthetics in small animals have direct relevance for clinical practice.
Conclusions
Deleterious brain structural effects during prolonged exposure to inhaled anaesthetics such as isoflurane and sevoflurane have been demonstrated in developing animals. On the other hand, dexmedetomidine has been observed to diminish injury during both brain ischaemia and isoflurane exposure. In a unique parallel study design involving two separate animal laboratories, we tested whether dexmedetomidine protected during a prolonged exposure to sevoflurane, the most frequently utilized paediatric anaesthetic, and whether escalating doses of dexmedetomidine by itself provided surgical levels of anaesthesia and produced any measurable neuronal injury. Dexmedetomidine did not increase neuroapoptosis compared with physiological neuronal death in the majority of brain regions examined, whereas a clinically relevant concentration of sevoflurane did. Even in the highest dose, dexmedetomidine did not increase the same level of anaesthesia or pain control as sevoflurane. We did not observe protective effects of dexmedetomidine supplementation during sevoflurane exposure. Accordingly, future studies should focus on the volatile anaesthetic dose-sparing effect of dexmedetomidine.
